All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants regenerative medicine advanced therapy (RMAT) designation to tisagenlecleucel for patients with relapsed or refractory follicular lymphoma
On April 22, 2020, tisagenlecleucel was granted regenerative medicine advanced therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL).1
Tisagenlecleucel is an anti‐CD19 chimeric antigen receptor T cell (CAR T cell) and currently has indications in R/R pediatric and young adult acute lymphoblastic leukemia and R/R adult diffuse large B-cell lymphoma. If approved, R/R FL will be the third indication for tisagenlecleucel. This RMAT designation for tisagenlecleucel in FL was based on preliminary data from the ongoing multicenter phase II ELARA study in adult patients with R/R FL.
U.S. FDA regulatory filing for tisagenlecleucel in R/R FL is anticipated in 2021.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?